Intra-Cellular Therapies (NASDAQ:ITCI) Research Coverage Started at StockNews.com

by · The Markets Daily

StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Piper Sandler reissued a “neutral” rating and set a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $132.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus target price of $109.70.

Check Out Our Latest Research Report on Intra-Cellular Therapies

Intra-Cellular Therapies Price Performance

ITCI opened at $131.87 on Wednesday. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The business has a fifty day simple moving average of $131.73 and a 200-day simple moving average of $111.89. Intra-Cellular Therapies has a fifty-two week low of $64.09 and a fifty-two week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, equities research analysts anticipate that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Trading of Intra-Cellular Therapies

Several large investors have recently added to or reduced their stakes in ITCI. Accredited Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at $28,000. MassMutual Private Wealth & Trust FSB raised its holdings in Intra-Cellular Therapies by 124.3% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 133 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth about $96,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at about $97,000. 92.33% of the stock is owned by institutional investors.

Intra-Cellular Therapies Company Profile

(Get Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Read More